신경혈관 기기 시장 : 제품 유형, 적응증, 임상 시술, 최종 사용자, 유통 채널별 - 세계 시장 예측(2026-2032년)

The Neurovascular Devices Market is projected to grow by USD 9.33 billion at a CAGR of 7.57% by 2032.

Neurovascular Devices Market Introduction

Neurovascular devices support the diagnosis and endovascular treatment of ischemic stroke, intracranial aneurysms, arteriovenous malformations, carotid artery disease, and other cerebrovascular disorders. Demand is tied to a clear clinical need: the World Stroke Organization reports more than 12 million new strokes annually worldwide, and stroke remains one of the leading causes of death and long-term disability.

The market is shaped by mechanical thrombectomy devices, aspiration catheters, stent retrievers, embolic coils, flow diverters, intracranial stents, guidewires, microcatheters, and access systems. Growth is increasingly evidence-led, with hospitals prioritizing devices that improve recanalization, reduce procedure time, support distal access, and align with guideline-based stroke and aneurysm care.

Transformative Shifts in Neurovascular Care

The neurovascular devices landscape is moving from procedure-specific tools toward integrated stroke and aneurysm care platforms. Randomized clinical trials have established mechanical thrombectomy as standard care for eligible large vessel occlusion stroke, expanding investment in comprehensive stroke centers, rapid imaging, and hub-and-spoke referral networks.

A second shift is the rise of next-generation aneurysm treatment, including lower-profile flow diverters, intrasaccular devices, and adjunctive coil technologies. At the same time, regulatory expectations for real-world evidence, post-market surveillance, and device traceability are increasing, especially in the United States and European Union.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming cumulative rather than isolated in neurovascular care. FDA-cleared and CE-marked AI tools already support CT, CTA, and perfusion imaging triage for suspected large vessel occlusion, helping stroke teams prioritize time-sensitive transfers and treatment decisions.

The larger opportunity is workflow orchestration. AI can connect image interpretation, emergency alerts, catheter lab readiness, inventory planning, and outcomes tracking. Industry leaders must validate algorithms across diverse populations because stroke presentation, scanner protocols, and access to thrombectomy-capable centers vary significantly by region.

Regional Insights Across Global Markets

North America remains a high-adoption region for neurovascular devices, supported by established stroke networks, FDA pathways, reimbursement infrastructure, and a large installed base of advanced CT, MRI, and angiography imaging. Europe shows strong demand through comprehensive stroke centers, aneurysm programs, and guideline-driven thrombectomy pathways, while the EU Medical Device Regulation raises evidence, clinical evaluation, post-market surveillance, and compliance requirements for neurointerventional products.

Asia-Pacific is expanding as China, India, Japan, South Korea, and Australia invest in stroke systems, specialist training, emergency imaging, and neurointerventional capacity to address a substantial cerebrovascular disease burden. Latin America is gaining traction through tertiary hospitals and public-private investments, with Mexico and Brazil anchoring procedural demand; however, reimbursement gaps and regional disparities continue to affect access. The Middle East benefits from healthcare infrastructure development and demand for advanced stroke and aneurysm care, particularly in high-investment health systems, while Africa presents long-term need-driven opportunity constrained by limited 24/7 neurointerventional services, workforce shortages, and uneven imaging availability.

Strategic Group Insights

ASEAN markets are strengthening stroke care capacity through public hospital investment, regional centers of excellence, and expanding access to CT angiography and catheterization infrastructure, though adoption varies by reimbursement and specialist availability. The GCC benefits from high healthcare spending, medical city development, and demand for premium neurointerventional systems, with procurement increasingly linked to clinical outcomes, physician training, and international accreditation standards. The European Union remains influential through MDR compliance, health technology assessment, clinical evidence expectations, and cross-border standards for device safety, traceability, and post-market performance.

BRICS countries represent scale-driven opportunity where stroke burden is high, hospital modernization is ongoing, and local manufacturing or localization policies influence procurement and regulatory strategy. G7 markets emphasize premium innovation, randomized and real-world evidence, functional outcome improvement, and reimbursement value for thrombectomy, aneurysm embolization, and flow diversion technologies. NATO countries overlap substantially with advanced hospital infrastructure and emergency care systems, but neurovascular device purchasing still differs by national health system design, budget cycles, tender processes, and domestic clinical priorities.

Country-Level Neurovascular Device Insights

The United States leads in FDA-cleared stroke treatment devices, mechanical thrombectomy adoption, advanced imaging use, and neurovascular clinical trial activity, while Canada emphasizes organized stroke systems, evidence-based procurement, and coordinated care pathways across provincial health networks. Mexico and Brazil offer growth through tertiary hospitals, expanding private healthcare capacity, and rising stroke awareness, though reimbursement limitations and regional disparities affect timely access to neurointerventional treatment.

In Europe, the United Kingdom, Germany, France, Italy, and Spain support advanced neurovascular care through specialized stroke centers, aneurysm programs, national or regional thrombectomy pathways, and clinical guideline adoption. Germany and France benefit from strong hospital infrastructure and procedural expertise, the United Kingdom continues to expand thrombectomy access through organized stroke networks, and Italy and Spain show demand from established neurology and interventional neuroradiology centers. Russia faces access variability linked to geography, infrastructure, and specialist distribution.

China, India, Japan, Australia, and South Korea are central to Asia-Pacific neurovascular device growth, driven by aging populations, high stroke burden, rising awareness, emergency imaging expansion, and regulatory modernization. China is advancing stroke center development and domestic device capability, India is expanding tertiary neurointervention services amid significant access gaps, Japan has mature endovascular expertise supported by an aging population, Australia benefits from coordinated stroke systems across major cities, and South Korea combines advanced hospital infrastructure with strong adoption of image-guided neurointerventional care.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinical differentiation over device breadth alone. Evidence on first-pass effect, complete reperfusion, complication reduction, aneurysm occlusion durability, retreatment reduction, and long-term functional outcomes is essential for payer acceptance, hospital purchasing, and guideline-aligned adoption.

Companies should pair device innovation with physician training, AI-enabled workflow partnerships, and service models that improve door-to-imaging, door-to-puncture, and reperfusion timelines. Regional strategies must address reimbursement, local regulatory evidence, health technology assessment, physician education, tender requirements, and supply resilience for catheters, coils, stents, flow diverters, and thrombectomy systems.

Research Methodology

This executive summary is based on a structured research approach using verified public sources, including World Health Organization and World Stroke Organization disease-burden data, FDA device databases, clinical trial registries, peer-reviewed stroke and neurointervention literature, clinical practice guidelines, and regional regulatory guidance.

Market interpretation combines secondary research with industry benchmarking across product categories, care settings, reimbursement environments, regulatory pathways, and adoption barriers. Insights are validated through consistency checks across clinical guidelines, regulatory records, hospital procurement trends, technology adoption patterns, and publicly available healthcare infrastructure indicators.

Conclusion: Evidence-Led Growth Outlook

The neurovascular devices market is positioned for sustained evidence-led growth as stroke systems mature, aneurysm technologies advance, and AI improves triage and workflow coordination. The strongest opportunities will favor devices that demonstrate measurable clinical value and fit seamlessly into emergency neurovascular pathways.

Future competitiveness will depend on regulatory readiness, real-world outcomes, physician training, reimbursement alignment, and regional access strategies. Companies that combine innovation with data, service support, and equitable market expansion will be best placed to lead in neurovascular intervention.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Neurovascular Devices Market, by Product Type

• 7.1. Embolization Devices
  • 7.1.1. Coil Embolization Devices
  • 7.1.2. Liquid Embolic Systems
  • 7.1.3. Flow Diversion Stents
• 7.2. Angioplasty & Stenting Systems
• 7.3. Neurothrombectomy Devices
  • 7.3.1. Stent Retrievers
  • 7.3.2. Aspiration/Suction Devices
  • 7.3.3. Mechanical Clot Retrievers/Snares
  • 7.3.4. Hybrid Devices
• 7.4. Support & Access Devices
  • 7.4.1. Microcatheters
  • 7.4.2. Guidewires
  • 7.4.3. Balloon Catheters

8. Neurovascular Devices Market, by Indication

• 8.1. Cerebral Aneurysms
• 8.2. Ischemic Stroke
• 8.3. Arteriovenous Malformations (AVMs) & Fistulas
• 8.4. Carotid Artery & Intracranial Stenosis
• 8.5. Hemorrhagic Stroke

9. Neurovascular Devices Market, by Clinical Procedure

• 9.1. Mechanical Thrombectomy
• 9.2. Aneurysm Occlusion
• 9.3. Flow Diversion
• 9.4. Carotid Artery Stenting (CAS)
• 9.5. Intracranial Stenting

10. Neurovascular Devices Market, by End User

• 10.1. Ambulatory Surgical Centers
  • 10.1.1. Hospital Affiliated Centers
  • 10.1.2. Independent Centers
• 10.2. Hospitals
• 10.3. Specialty Clinics
• 10.4. Research Laboratories & Academic Institutions

11. Neurovascular Devices Market, by Distribution Channel

• 11.1. Direct Sales
• 11.2. Online Sales
• 11.3. Third Party Distributors

12. Neurovascular Devices Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Neurovascular Devices Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Neurovascular Devices Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Stryker Corporation
• 16.2. Medtronic plc
• 16.3. Johnson & Johnson
• 16.4. Penumbra, Inc.
• 16.5. Terumo Corporation
• 16.6. Kaneka Corporation
• 16.7. BALT Group
• 16.8. MicroPort Scientific Corporation
• 16.9. ASAHI INTECC CO., LTD.
• 16.10. Koninklijke Philips N.V.
• 16.11. Endologix Inc.
• 16.12. Integer Holdings Corporation
• 16.13. Secant Group, LLC by Solesis Group
• 16.14. Imperative Care, Inc.
• 16.15. Medical Murray, Inc.
• 16.16. Phenox GmbH
• 16.17. Zeus Company LLC
• 16.18. Acandis GmbH
• 16.19. Rapid Medical Ltd.
• 16.20. Sino Medical Sciences Technology Inc.
• 16.21. NeuroSafe Medical Co., Ltd.
• 16.22. Scientia Vascular, Inc.
• 16.23. Anaconda Biomed S.L.
• 16.24. ArtVentive Medical Group, Inc.
• 16.25. Evasc Medical Systems Corp
• 16.26. InspireMD Inc.
• 16.27. iVascular S.L.U.
• 16.28. MIVI Neuroscience, Inc.
• 16.29. NeuroVasc Technologies Inc.
• 16.30. Nventric, Inc.
• 16.31. Q'Apel Medical Inc.
• 16.32. Radical Catheter Technologies, Inc.
• 16.33. Route 92 Medical, Inc.
• 16.34. Vesalio, LLC
• 16.35. Wallaby Medical Holding, Inc..
• 16.36. ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD.